Circio Holding ASA (TA50.F)
Frankfurt · EUR · Healthcare · Biotechnology
€1.07 (+4.28%) as of
Key statistics
- Market cap
- 311.92M
- EPS (TTM)
- -0.0300
- Dividend yield
- 0.00%
- 52-week range
- 0.0673 – 1.3300
- Beta
- -1.03
- Profit margin
- 0.00%
- Volume
- 110.00
About Circio Holding ASA
Circio Holding ASA, a biotechnology company, develops novel circular RNA expression technology for gene and cell therapy. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. It has a research collaboration with United Immunity Co., Ltd. for the development of vivo CAR-Macrophage (CAR-M) therapy; and Suzhou GenAssist Therapeutics Co., Ltd. to develop circVec-enhanced AAV vectors engineered for in vivo cell therapy and low dose systemic gene therapy. The company was formerly known as Targovax ASA and changed its name to Circio Holding ASA in May 2023. Circio Holding ASA was incorporated in 2010 and is based in Oslo, Norway.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Oslo, Norway
- Employees
- 10
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.